Mukul Agarwal

Corporate Officer/Principal presso FORTY SEVEN, INC.

Consumer Services

Health Technology

Profilo

Mukul Agarwal is currently the Vice President of Corporate Development at Forty Seven, Inc. Prior to this, he worked as the Senior Director of Corporate Development and Strategy at Anacor Pharmaceuticals LLC.
From 2016 to 2019, he was the Vice President of Business Development at Revance Therapeutics, Inc. Mr. Agarwal holds a Master's in Business Administration from Carnegie Mellon University, a graduate degree from The Ohio State University, and an undergraduate degree from the Indian Institute of Technology New Delhi.

Posizioni attive di Mukul Agarwal

Società	Posizione	Inizio
FORTY SEVEN, INC.	Corporate Officer/Principal	-

Tutte le posizioni attive di Mukul Agarwal

Precedenti posizioni note di Mukul Agarwal

Società	Posizione	Fine
REVANCE THERAPEUTICS, INC.	Corporate Officer/Principal	01/03/2019
ANACOR PHARMACEUTICALS INC	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Mukul Agarwal

Formazione di Mukul Agarwal

Carnegie Mellon University	Masters Business Admin
The Ohio State University	Graduate Degree
Indian Institute of Technology New Delhi	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Mukul Agarwal

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
REVANCE THERAPEUTICS, INC.	Health Technology

Aziende private	2
Anacor Pharmaceuticals LLC Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA.	Health Technology
Forty Seven, Inc. Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.	Health Technology

Aziende private